Oncology nurses play essential roles in the emerging field of cardio-oncology, which aims to protect patients’ heart function ...

Pharmac has today announced their decision to fund six medicines for cancer, including a combination treatment, and one ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...

Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.

Such a head-to-head trial was conducted by GlaxoSmithKline to compare their tyrosine kinase inhibitor, pazopanib, to another tyrosine kinase inhibitor, sunitinib, in 1110 patients with metastatic ...

Correlates of immunotherapy response in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes. Association of baseline KIM-1 and KIM-1 change on treatment with outcomes.

Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report. Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma ...

Examined against the targeted cancer drug sunitinib, results saw the arm treated with combination therapy achieving a median OS of 46.5 months. Credit: Shutterstock / sasirin pamai. Five-year results ...

Abstract 439: CheckMate 9ER Trial At the ASCO GU meeting, final follow-up results from CheckMate 9ER, comparing the combination of nivolumab and cabozantinib to sunitinib (Sutent)in untreated aRCC, ...

CheckMate 9ER evaluated the combination compared to sunitinib. Patients receiving the combination had a higher response rate and superior quality of life. Over the long term, patients benefitted ...

Background: In a recent randomized, phase 3 trial (CheckMate 9ER), nivolumab combined with cabozantinib significantly improved patient outcomes compared with sunitinib. However, the cost-effectiveness ...